CB-ChMF-12 demonstrated strong in-vitro anti-angiogenic action and inhibited the expression of pivotal oncogenes in the tumoral tissue, thus limiting cancer growth and metastatization. Therapeutic assumption: after the treatment with CB-ChMF-12, the constrained tumor can be easily and safely treated with traditional surgery.
CB-ChMF-12 is a cocktail of molecules naturally produced by human preeclamptic PDMSCs. We believe our approach offers a unique opportunity to treat epithelial cancers with a lower level of toxicity compared with current chemio-therapics.
CB-ChMF-12 therapeutic approach for Epithelial Tumors treatment is granted in Italy and pending in Europe, USA, Canada, China, Japan.